Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Inflammatory breast cancer, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Diagnosis is delayed because the picture is mistaken for infection.
No molecular driver of the inflammatory phenotype has been found.
Trials restricted to inflammatory disease are rare, so treatment is extrapolated.
Local recurrence on the chest wall remains common in poor responders despite radiotherapy.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
3-year iDFS 92.
iDFS HR 0.
A milestone in how this cancer is treated.
EFS HR 0.
iDFS HR 0.